Showing results (161-170 of 358) with videos related to

Sort By:
Pageof 36
Journal of Diabetes Research|May 28, 2013
Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetesLeslie P Cousens, Yan Su, Elizabeth McClaine, et al.
Acta Biomaterialia|March 26, 2019
Fabrication and mechanical characterization of 3D printed vertical uniform and gradient scaffolds for bone and osteochondral tissue engineeringSean M Bittner, Brandon T Smith, Luis Diaz-Gomez, et al.
Blood Advances|May 13, 2026
HNRNPU Mutations Redirect Cell Cycle Control to E2F in MYC-Driven LymphomasQuratulain Qureshi, Krysta Mila Coyle, Callum Brown, et al.
Blood Cancer Discovery|May 12, 2026
Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell LymphomaMargaret A Shipp, Louis M Staudt, Daniel J Hodson, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 21, 2014
The pathogenic mechanism of diabetes varies with the degree of overexpression and oligomerization of human amylin in the pancreatic islet β cellsShaoping Zhang, Hong Liu, Chia Lin Chuang, et al.
Tissue Engineering. Part A|January 20, 2021
Swelling Behaviors of 3D Printed Hydrogel and Hydrogel-Microcarrier Composite ScaffoldsSean M Bittner, Hannah A Pearce, Katie J Hogan, et al.
Human Vaccines & Immunotherapeutics|October 26, 2012
Teaching tolerance: New approaches to enzyme replacement therapy for Pompe diseaseLeslie P Cousens, Federico Mingozzi, Sander van der Marel, et al.
Blood Cancer Journal|March 14, 2018
Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine eraRebecca L King, Grzegorz S Nowakowski, Thomas E Witzig, et al.
Blood Advances|February 11, 2021
Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumorsVignesh Shanmugam, Jeffrey W Craig, Laura K Hilton, et al.
Blood Advances|August 1, 2020
Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphomaDiego Villa, Laurie H Sehn, Kerry J Savage, et al.
Pageof 36